Search results for " her-2"
showing 7 items of 7 documents
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review
2018
Introduction: The introduction of monoclonal antibodies (moAbs) into clinical practice revolutionized the treatment strategies in several solid tumors. These agents differ from cytotoxic chemotherapy for their mechanism of action and toxicity. By targeting specific antigens present on healthy cells and modulating immune system activity, these biological drugs are able to generate a wide spectrum of peculiar adverse events that can negatively impact on patients' quality of life. Areas covered: In this review, the main side effects associated with the use of moAbs have been described to show their incidence and current management strategies, which may drive clinicians in their daily practice.…
2-Triazenoazaindoles: Α novel class of triazenes inducing transcriptional down-regulation of EGFR and HER-2 in human pancreatic cancer cells
2012
Pancreatic cancer is a complex malignancy arising from the accumulation of genetic and epigenetic defects in the affected cells. Standard chemotherapy for patients with advanced disease shows only modest effects and is associated with considerable toxicity. Overexpression or aberrant activation of members of the epidermal growth factor receptor tyrosine kinase family, which includes EGFR and HER-2, occurs frequently and is associated with multiple drug resistance and decreased patient survival. In this study, we have investigated the therapeutic potential of AS104, a novel compound of the triazene class, with potential inhibitory effects on EGFR. We found that treatment of cells with AS104 …
“Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with metastatic (M) breast cancer (BC): r…
2009
Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective
2018
Antineoplastic drugs can be associated with several side effects, including cardiovascular toxicity (CTX). Biochemical studies have identified multiple mechanisms of CTX. Chemoterapeutic agents can alter redox homeostasis by increasing the production of reactive oxygen species (ROS) and reactive nitrogen species RNS. Cellular sources of ROS/RNS are cardiomyocytes, endothelial cells, stromal and inflammatory cells in the heart. Mitochondria, peroxisomes and other subcellular components are central hubs that control redox homeostasis. Mitochondria are central targets for antineoplastic drug-induced CTX. Understanding the mechanisms of CTX is fundamental for effective cardioprotection, without…
Morphological and biomolecular charachteristics of subcentimetric invasive breast carcinomas: a sicilian multicentric retrospective analysis
2010
HER-2 marķiera noteikšana krūts vēža pacientēm neoadjuvantas ķīmijterapijas laikā
2021
Ievads. Onkomarķieriem ir īpaša nozīme ļaundabīgo slimību diagnostikā un ārstēšanas efektivitātes prognozēšanā. HER-2 receptora ekspresija raksturīga vidēji 15-30% krūts vēža audzējiem un ir saistīta ar agresīvu audzēja gaitu. Audzēja HER-2 ekspresiju nosaka biopsijas materiālā. Savukārt, ekstracelulāro HER-2 domēnu iespējams noteikt asins serumā. Seruma HER-2 var būt noteikts arī veseliem pacientiem, taču, tā koncentrācija ir augstāka pacientiem ar krūts vēzi, īpaši ja audzējs ir HER-2 receptoru pozitīvs. Izteikts seruma HER-2 koncentrācijas samazinājums ķīmijterapijas laikā var būt saistīts ar labāku atbildi uz terapiju, ilgāku laiku līdz slimības progresijai un garāku kopējo dzīvildzi. D…